John H. Strickler, MD, Duke Cancer Institute
Advertisement
Articles by John H. Strickler, MD, Duke Cancer Institute
Advertisement
Latest Updated Articles
Treatments for BRAF-Mutated mCRCPublished: April 16th 2021 | Updated:
Regorafenib as Later-Line Treatment for mCRCPublished: April 23rd 2021 | Updated:
Novel Combinations Being Investigated for mCRC TreatmentPublished: May 21st 2021 | Updated:
BRAF-Mutated mCRC: Treating With the BEACON RegimenPublished: April 23rd 2021 | Updated:
Applying Aggressive Therapy to Treat mCRC Up FrontPublished: April 2nd 2021 | Updated:
Maintenance Therapy for Metastatic CRCPublished: April 9th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5